SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the
SAN DIEGO, Calif. – August 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for onvuzosiran, an
– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D – – Robert Ackles joins as Chief People Officer, bringing nearly three decades of biopharma leadership experience and a proven record of
SAN DIEGO, Calif. – June 8, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that Phase 1/2 clinical data for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate
– Brings more than 20 years of experience in investment banking advising biotech and other innovative growth companies on financial and corporate development strategy – SAN DIEGO, Calif. – March 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage biotechnology company developing
– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – SAN DIEGO, Calif. – February 27, 2026 – ADARx Pharmaceuticals, Inc.
SAN DIEGO, Calif. – February 20, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present Phase 1/2 clinical data and Phase 3 design for its onvuzosiran (also known asADX-324)
– Seasoned clinical development leader brings more than 25 years of deep expertise in clinical development and operations across biotech and healthcare industry – SAN DIEGO, Calif. – February 5, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage biotechnology company developing
